Reprogrammed Stem Cells Show Promise for Healing Chronic Wounds That Refuse to Close

Chronic wounds, defined as injuries that fail to progress through the normal healing process within three months, represent one of the most stubborn challenges in modern medicine. They include diabetic foot ulcers, vascular ulcers, and pressure sores, and their prevalence is climbing sharply as populations age and rates of diabetes, obesity, and vascular disease rise. For patients, the consequences can be devastating: persistent pain, infection, impaired mobility, amputation, and even death. Current statistics are sobering. Only about half of diabetic foot ulcers heal within twelve to twenty weeks, and half of those recur within eighteen months. Among elderly patients with multiple complicating conditions, roughly thirty percent require amputation and a quarter of them die from the condition. Against this backdrop, a new narrative review published in BMC Plastic and Reconstructive Surgery takes stock of one of the most exciting frontiers in regenerative medicine: induced pluripotent stem cells, or iPSCs, and their emerging role in coaxing stubborn wounds to heal.

The review, led by Yuyao Lin and Yujie Yan of the First Affiliated Hospital of Xi’an Jiaotong University, synthesizes preclinical evidence across three major therapeutic platforms: iPSC-derived cells, iPSC-derived extracellular vesicles, and three-dimensional tissue-engineered skin substitutes. The authors argue that iPSCs hold several decisive advantages over both embryonic stem cells and adult stem cells currently under investigation. Because iPSCs are generated by reprogramming a patient’s own easily obtained cells, such as skin fibroblasts or blood cells, they sidestep the ethical controversies surrounding embryo-derived material and eliminate the need for invasive harvesting procedures like bone marrow aspiration or fat biopsies. Once reprogrammed using the now-famous quartet of transcription factors identified by Shinya Yamanaka, OCT-3/4, SOX2, c-MYC, and KLF4, iPSCs regain the pluripotency of embryonic cells, meaning they can in principle become every cell type found in healthy skin.

That versatility is precisely what chronic wounds need. Normal healing unfolds through four overlapping phases: coagulation, inflammation, migration and proliferation, and remodeling. Chronic wounds stall somewhere in this choreography, exhibiting impaired growth factor production, reduced angiogenesis, elevated inflammatory markers, and poor cellular proliferation. In diabetes, persistent hyperglycemia disrupts inflammation, angiogenesis, vascular permeability, and endothelial progenitor cell function all at once. The review details how iPSC-derived mesenchymal stem cells, endothelial cells, vascular smooth muscle cells, fibroblasts, epithelial stem cells, and keratinocytes each target a different failure point. In wounded immunodeficient mice, for example, iPSC-derived mesenchymal cells established even from a patient with recessive dystrophic epidermolysis bullosa produced detectable human type VII collagen at the dermal-epidermal junction of healed tissue, demonstrating biological activity relevant to skin repair.

The vascular story is particularly compelling. Angiogenesis, the growth of new blood vessels from pre-existing ones, is essential for restoring oxygen and nutrient delivery to injured tissue, and it is markedly impaired in chronic and diabetic wounds. The review describes how iPSC-derived endothelial cells applied topically to excisional wounds accelerated closure and perfusion-linked outcomes in preclinical models. Even more striking, co-implantation of iPSC-derived endothelial cells with iPSC-derived vascular smooth muscle cells produced enhanced angiogenesis, greater arteriole density, and faster wound healing than endothelial cells alone. Vascular smooth muscle cells embedded in collagen scaffolds secrete a cocktail of pro-repair mediators, including VEGF-A, basic fibroblast growth factor, and IL-10, collectively supporting vessel formation while tempering inflammation in both acute and diabetic wound models.

Perhaps the most strategically important finding is that many of these benefits do not require the transplanted cells to survive at all. Longitudinal tracking using firefly luciferase reporter genes revealed that iPSC-derived endothelial cells showed a substantial and progressive decline in survival over time, yet the therapeutic benefits persisted. The explanation lies in paracrine signaling: cells secrete extracellular vesicles, tiny membrane-bound packages loaded with proteins, lipids, and regulatory RNAs, that reprogram the behavior of recipient cells in the wound bed. This insight has spawned a cell-free therapeutic paradigm. Extracellular vesicles harvested from iPSC-derived cells offer advantages in manufacturing, storage, and delivery, and because they are acellular and non-replicative, they are not expected to form teratomas, the tumors that can arise from residual undifferentiated pluripotent cells.

The mechanistic detail emerging from this work is remarkable. Recent studies show that exosomes from iPSC-derived mesenchymal stem cells promote wound healing by delivering FGF2 to the FGFR3 receptor on keratinocytes, activating the p38 pathway to enhance proliferation and migration while dampening inflammation. Another team demonstrated that microvesicles from iPSCs accelerate deep second-degree burn healing through a specific microRNA cargo, miR-16-5p, that boosts keratinocyte migration. In diabetic mouse models, iPSC-derived extracellular vesicles coupled pro-vascularization signals with strong anti-inflammatory activity, shifting macrophage states toward repair and inhibiting T-cell proliferation. Meanwhile, engineered skin substitutes built entirely from iPSC-derived keratinocytes and fibroblasts have achieved increasingly human-like architecture, and a landmark study generated hair-bearing skin from pluripotent stem cells that integrated seamlessly with host tissue without ulcers or tumors.

Yet the review is notably candid about the obstacles standing between bench and bedside. The most serious is tumorigenicity. Even a minuscule residual fraction of undifferentiated cells, on the order of 0.01 percent, can give rise to teratomas, and standard flow cytometry typically detects rogue pluripotent cells only at frequencies around 0.1 percent. Reprogramming itself can inflict genomic damage, and reactivation of the c-MYC oncogene has produced somatic tumors in animal models. Safer non-integrative approaches, including Sendai virus vectors, episomal plasmids, and even purely chemical reprogramming using small molecules, are advancing rapidly, but the authors stress that no current quality control method can guarantee complete elimination of pluripotent contaminants.

Immunocompatibility presents a second frontier. Autologous iPSC therapies avoid rejection but are slow, expensive, and potentially compromised by the patient’s own disease: cells from diabetic patients carry epigenetic memory and metabolic dysfunction that can persist after reprogramming, and iPSC-derived endothelial cells from obese diabetic mice show impaired function compared with healthy controls. Allogeneic, off-the-shelf products from healthy young donors promise scalability and standardized manufacturing, but require immune engineering. Researchers have used CRISPR-Cas9 to create hypoimmunogenic universal iPSC lines by disrupting HLA class I and II expression while preserving HLA-E or HLA-C, or by overexpressing the CD47 don’t-eat-me signal. One such strategy of twelve HLA-C-retained lines could theoretically match more than ninety percent of the world’s population. The catch is that dampening immune recognition may also blunt immune surveillance against emerging tumors, prompting calls for built-in suicide switches such as ganciclovir-sensitive thymidine kinase genes.

Practical and economic hurdles loom as well. Manufacturing clinical-grade iPSC products is estimated to cost between five thousand and fifty thousand dollars per line, before accounting for GMP facility infrastructure and rigorous quality release testing. Tissue-engineered skin substitutes still lack functional vasculature, nerves, sweat glands, and immune cells, and without rapid vascular inosculation, grafts cannot survive beyond a certain thickness. The review also emphasizes that most evidence comes from small rodent models with short follow-up, heterogeneous dosing, and inconsistent endpoints, and that no head-to-head trials have yet demonstrated clear superiority of iPSC-derived products over adult stem cells or advanced dressings. Still, the authors conclude that iPSCs should be viewed not as a universal cure but as an adaptable regenerative platform whose value depends on implementation. With standardized potency assays, clinically relevant large-animal models, and rigorous long-term safety assessment under GMP-compatible workflows, reprogrammed cells and their vesicles could ultimately transform care for millions of patients whose wounds simply refuse to heal.

Subject of Research: Induced pluripotent stem cell-based therapies for chronic wound healing

Article Title: Application and progress of induced pluripotent stem cells in chronic wound healing: a narrative review

Article References: Application and progress of induced pluripotent stem cells in chronic wound healing: a narrative review. (n.d.). https://doi.org/10.1186/s44452-026-00016-w

Image Credits: AI Generated

DOI: 10.1186/s44452-026-00016-w

Keywords: induced pluripotent stem cells, chronic wounds, wound healing, extracellular vesicles, tissue-engineered skin substitutes, diabetic foot ulcers, angiogenesis, regenerative medicine, tumorigenicity, immunocompatibility, cell therapy, mesenchymal stem cells